BSE
ASTRAZEN

ASTRAZENECA PHARMA INDIA LTD.

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

ASTRAZENECA PHARMA INDIA LTD. Stock Price

Vitals

Today's Low:
₹4370
Today's High:
₹4555.75
Open Price:
₹4511.9502
52W Low:
₹2926.6176
52W High:
₹4254.6499
Prev. Close:
₹4511.8999
Volume:
1309

Company Statistics

Market Cap.:
₹101.50 billion
Book Value:
235.476
Revenue TTM:
₹10.03 billion
Operating Margin TTM:
0%
Gross Profit TTM:
₹6.43 billion
Profit Margin:
0%
Return on Assets TTM:
10.11%
Return on Equity TTM:
18.05%

Company Profile

ASTRAZENECA PHARMA INDIA LTD. had its IPO on under the ticker symbol ASTRAZEN.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. ASTRAZENECA PHARMA INDIA LTD. has a staff strength of 947 employees.

Stock update

Shares of ASTRAZENECA PHARMA INDIA LTD. opened at ₹4511.95 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹4370 - ₹4555.75, and closed at ₹4475.2.

This is a -0.81% slip from the previous day's closing price.

A total volume of 1,309 shares were traded at the close of the day’s session.

In the last one week, shares of ASTRAZENECA PHARMA INDIA LTD. have increased by +4.27%.

ASTRAZENECA PHARMA INDIA LTD.'s Key Ratios

ASTRAZENECA PHARMA INDIA LTD. has a market cap of ₹101.50 billion, indicating a price to book ratio of 15.5412 and a price to sales ratio of 9.3798.

In the last 12-months ASTRAZENECA PHARMA INDIA LTD.’s revenue was ₹10.03 billion with a gross profit of ₹6.43 billion and an EBITDA of ₹1.61 billion. The EBITDA ratio measures ASTRAZENECA PHARMA INDIA LTD.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, ASTRAZENECA PHARMA INDIA LTD.’s operating margin was 0% while its return on assets stood at 10.11% with a return of equity of 18.05%.

In Q2, ASTRAZENECA PHARMA INDIA LTD.’s quarterly earnings growth was a negative -38.3% while revenue growth was a positive 22.7%.

ASTRAZENECA PHARMA INDIA LTD.’s PE and PEG Ratio

Forward PE
0
Trailing PE
102.5771
PEG

Its diluted EPS in the last 12-months stands at ₹39.58 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ASTRAZENECA PHARMA INDIA LTD.’s profitability.

ASTRAZENECA PHARMA INDIA LTD. stock is trading at a EV to sales ratio of 8.8477 and a EV to EBITDA ratio of 56.4358. Its price to sales ratio in the trailing 12-months stood at 9.3798.

ASTRAZENECA PHARMA INDIA LTD. stock pays annual dividends of ₹0 per share, indicating a yield of 0.4% and a payout ratio of 122.83%.

Balance sheet and cash flow metrics

Total Assets
₹9.85 billion
Total Liabilities
₹3.84 billion
Operating Cash Flow
₹0
Capital Expenditure
₹0
Dividend Payout Ratio
122.83%

ASTRAZENECA PHARMA INDIA LTD. ended 2024 with ₹9.85 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹9.85 billion while shareholder equity stood at ₹5.89 billion.

ASTRAZENECA PHARMA INDIA LTD. ended 2024 with ₹0 in deferred long-term liabilities, ₹3.84 billion in other current liabilities, 50000000.00 in common stock, ₹5.84 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹5.00 billion and cash and short-term investments were ₹5.11 billion. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.

ASTRAZENECA PHARMA INDIA LTD.’s total current assets stands at ₹8.35 billion while long-term investments were ₹0 and short-term investments were ₹105.70 million. Its net receivables were ₹1.08 billion compared to accounts payable of ₹2.28 billion and inventory worth ₹1.90 billion.

In 2024, ASTRAZENECA PHARMA INDIA LTD.'s operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, ASTRAZENECA PHARMA INDIA LTD. paid ₹1.23 in dividends in 2024.

Other key metrics

Current Trading Price
₹4475.2
52-Week High
₹4254.6499
52-Week Low
₹2926.6176
Analyst Target Price

ASTRAZENECA PHARMA INDIA LTD. stock is currently trading at ₹4475.2 per share. It touched a 52-week high of ₹4254.6499 and a 52-week low of ₹4254.6499. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹3975.7 and 200-day moving average was ₹3503.11 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 8339.2% of the company’s stock are held by insiders while 377.7% are held by institutions.

Frequently Asked Questions About ASTRAZENECA PHARMA INDIA LTD.

The stock symbol (also called stock or share ticker) of ASTRAZENECA PHARMA INDIA LTD. is ASTRAZEN

The IPO of ASTRAZENECA PHARMA INDIA LTD. took place on

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
₹1168.9
-73.8
-5.94%
₹499.9
-15.85
-3.07%
₹107
-5.4
-4.8%
₹34.68
0.53
+1.55%
₹46.5
-0.61
-1.29%
₹37.27
-0.1
-0.27%
₹0.92
-0.01
-1.08%
₹57.99
0.81
+1.42%
₹0.51
0.01
+2%
₹1.84
0.06
+3.37%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
₹0.14
0.07
+100%
₹0.12
0.04
+45.29%
₹0.96
0.05
+5.4%
₹1.34
-0.35
-20.71%
Humbl Inc (HMBL)
₹0
0
0%

Top Gainers

Last Price
Chg
Chg%
₹0
0
+172200%
₹0
0
+51200%
₹283
280.03
+9428.62%
₹11.2
10.57
+1667.68%
Latch Inc (LTCHW)
₹0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
₹0.19
-123.15
-99.85%
₹0
-0.11
-99.55%
₹0
-0
-97.96%
₹0
-0.01
-93.94%
₹0.01
-0.06
-92.24%

About

AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brand names; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brand names. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Address